Synergy rockets on Phase III constipation data

Positive topline results from the first of two pivotal Phase III trials of Synergy Pharmaceuticals' chronic idiopathic constipation drug plecanatide have sent the company's share price soaring.

Positive topline results from the first of two pivotal Phase III trials of Synergy Pharmaceuticals' chronic idiopathic constipation drug plecanatide have sent the company's share price soaring.

Canaccord Genuity analyst Corey Davis commented that the data were the "best" that could have been hoped for. "Both doses,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category